Effects of Leptin Replacement Therapy on Pancreatic β-Cell Function in Patients With Lipodystrophy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Leptin administration is known to directly modulate pancreatic β-cell function in leptin-deficient rodent models. However, human studies examining the effects of leptin administration on β-cell function are lacking. In this study, we examined the effects (16–20 weeks) of leptin replacement on β-cell function in patients with lipodystrophy. RESEARCH DESIGN AND METHODS: In a prospective, open-label, currently ongoing study, we studied the effects of leptin replacement on β-cell function in 13 patients with congenital or acquired lipodystrophy. Insulin secretory rate (ISR) was calculated by C-peptide deconvolution from plasma glucose and C-peptide levels measured during oral glucose tolerance tests (OGTTs) performed at baseline and after 16–20 weeks of leptin replacement. β-Cell glucose sensitivity and rate sensitivity were assessed by mathematical modeling of OGTT. RESULTS: There was a significant decrease in triglycerides, free fatty acids, and glycosylated hemoglobin levels (A1C) after leptin therapy. Patients with lipodystrophy have high fasting and glucose-stimulated ISR. However, leptin therapy had no significant effect on fasting ISR, total insulin secretion during OGTT, β-cell glucose sensitivity, rate sensitivity, or insulin clearance. CONCLUSIONS: In contrast to the suppressive effects of leptin on β-cell function in rodents, 16–20-week treatment with leptin in lipodystrophy patients did not significantly affect insulin secretion or β-cell function in leptin-deficient individuals with lipodystrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215001 · Cited by 800 · cited 1×
“09), it is possible that a more sensitive method, such as the euglycemic-hyperinsulinemic clamp, would have detected improvements in insulin sensitivity as reported in prior studies (1,24,30).”
MethodKulkarni, R. N., Wang, Z. L., Wang, R. M., Hurley, J. D., Smith, D. M., Ghatei, M. A., Withers, D. J., Gardiner, J. V., Bailey, C. J., & Bloom, S. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119818 · Cited by 296 · cited 4×
“These findings have led some to speculate that the diminished responsiveness of pancreatic b-cells to the negative effects of leptin partly contributes to the hyperinsulinemia typically observed in obesity (4,7,8).”
BackgroundInfluentialSeufert, J., Kieffer, T. J., Leech, C. A., Holz, G. G., Moritz, W., Ricordi, C., & Habener, J. F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5460 · Cited by 278
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†
Javor, E. D., Ghany, M. G., Cochran, E. K., Oral, E. A., DePaoli, A. M., Premkumar, A., Kleiner, D. E., & Gorden, P. (2005) · Hepatology · doi:10.1002/hep.20672 · Cited by 228
Self-citationLong-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy
Javor, E. D., Cochran, E. K., Musso, C., Young, J. R., DePaoli, A. M., & Gorden, P. (2005) · Diabetes · doi:10.2337/diabetes.54.7.1994 · Cited by 226 · cited 6×
“Leptin therapy was provided as a self-administered once- or twice-daily subcutaneous injection as previously described (9,11).”
BackgroundMethodInfluentialSelf-citationSeufert, J., Kieffer, T. J., & Habener, J. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.2.674 · Cited by 193
Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
Kanat, M., Mari, A., Norton, L., Winnier, D., DeFronzo, R. A., Jenkinson, C., & Abdul-Ghani, M. A. (2012) · Diabetes · doi:10.2337/db11-0995 · Cited by 122
Self-citation
Cited by
Congenital generalized lipodystrophies—new insights into metabolic dysfunction
Patni, N., & Garg, A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.123 · Cited by 261
The JAK / STAT pathway in obesity and diabetes
Gurzov, E. N., Stanley, W. J., Pappas, E. G., Thomas, H. E., & Gough, D. J. (2016) · The FEBS Journal · doi:10.1111/febs.13709 · Cited by 249
Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives
Tchang, B. G., Shukla, A. P., & Aronne, L. J. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1052789 · Cited by 28
Adamski, K., Cook, K., Gupta, D., Morris, E., Tuttle, E., Carr, E., Cremasco, F., Cochran, E., & Brown, R. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1976125 · Cited by 11
Self-citationBrush, M., Auh, S., Cochran, E., Tuska, R., Koh, C., Kleiner, D. E., Lightbourne, M., & Brown, R. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae335 · Cited by 10
Self-citation
Metadata
- Authors
- Muniyappa, R., Brown, R. J., Mari, A., Joseph, J., Warren, M. A., Cochran, E. K., Skarulis, M. C., & Gorden, P.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-03-08
- Volume
- 37
- Issue
- 4
- Pages
- 1101-1107
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2161490648
- Cited by
- 24
- References
- 8
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.